It takes two: ‘No clinical AI solution can work on its own’

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: AI, Clinical trial, Real world data, Real world evidence

Clinical AI, no matter how sophisticated, cannot work on its own, says Life Image CEO, who predicts that CROs will either adapt or be disrupted by smaller companies with digital access capabilities.

Life Image has the world’s largest interoperable global network for accessing data and clinical endpoints, connecting 1,500 US hospitals with 150,000 providers and 58,000 global clinics to manage 10m clinical encounters per month, According to the company.

Its network collates an “ecosystem”​ of hospitals, clinicians, patients, care teams, life sciences, medical devices, telehealth, and electronic health records (EHRs). And with the ability to scale up to a population health level, CEO Matthew Michela said it can help advance clinical trials, incorporating imaging data into real world evidence (RWE) programs in life sciences.

As part of this, Life Image recently announced a strategic partnership with Mendel Health, a San Francisco, CA-headquartered company which uses artificial intelligence (AI) to examine unstructured data in medical literature and EHRs.

Through its partnership with Mendel, Life Image is using the platform to facilitate clinical trial site location as well as patient recruitment for oncology studies.

According to the company, Mendel Brain yields 30 to 50% more patients than traditional methods, using machine learning (ML) to process information and continuously improve outcomes to decrease the time between patient eligibility and identification.

“What makes the solution work in practice is connecting the technology to medical data, which requires both platform and clinical workflow integration that is supported by Life Image across its large network of hospitals and clinical trial sites,”​ Michela explained.

Mendel Brain also is focused specifically on oncology, which Michela said allows it increase precision in a therapeutic area. “The more general an AI, the poorer its performance will be when faced with any specific complex problem,”​ he explained.

Michela noted that creating innovative AI is a challenge – and up to 70% of AI products fail​, according to a panelist during the SCOPE Summit in February.

“Many of these types of solutions do not get put into practice because in order to actually work, they require integration into a wide array of data storage sites across a wide set of hospitals and clinical trial sites, all of which have different technology platforms,” ​Michela added.

Life Image addresses this challenge as it has built interoperable integrations into thousands of hospitals that support millions of patients monthly, across all types of physician workflows, he explained.

Still the need for scalable technology solutions integrated into the provider and hospital workflow will accelerate, as the amount of data sources continues to grow rapidly.

Among these sources is image data, which Michela predicts will “rapidly start”​ to be included in real world evidence (RWE), which he said will develop into the primary way clinical trials are conducted in both the pre- and post-markets.

He also predicts that contract research organizations (CROs) and the heavy manual process of collecting data will either adapt or be disrupted by smaller companies with digital access capabilities.”

Michela said, “No matter how sophisticated it is, no clinical AI solution can work on its own. It needs access to massive amounts of interoperable data at scale within the delivery system in order to have any utility.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more